A new era in CNS drug delivery: Crossing the blood brain barrier
Advances in neuroscience are reshaping our understanding of the brain and opening new frontiers in how we diagnose, treat, and ultimately prevent neurological...
Developing and launching a successful cell and gene therapy requires specialist expertise and out-of-the-box thinking to adapt to new business models and pricing strategies. CRA has significant experience in this space and understands the unique challenges that gene or cell therapies can bring to manufacturers and the healthcare industry. We bring industry-leading methodologies from clinical development through launch to support commercial, medical affairs, pricing, market access, and policy makers/regulators in navigating a rapidly evolving landscape.
Our offerings
We are gene therapy specialists.
CRA’s experience stems from more than 100 gene therapy engagements across multiple therapeutic areas.
- 50+Gene therapy engagements since 2022
- 20+Disease areas covered
Engagements
- 01Business development search to assess the commercial attractiveness of the gene therapy pipelineOur client sought to assess a broad range of indications in which gene therapy is being developed and create a comprehensive map of the landscape to facilitate...View engagement
- 02Commercial assessment of early-stage gene editing technology for sickle cell disease and β-thalassemiaOur client asked us to identify and prioritize opportunities for a technologically novel approach to gene editing for two indications in which it may be a late...View engagement
- 03Development of GTx site-readiness playbook for an investigational productCRA’s client, a multinational healthcare company, aimed to develop a site-readiness playbook to support launch planning for an investigational gene transfer...View engagement